Indeed, JQ1, a selective small-molecule bromodomain inhibitor, was able to inhibit both MYC transcription and MYC-related target genes, thus leading to inhibition of MM cell proliferation both in vitro and in vivo. This evidence concerns the gene MYC and Miyoshi myopathy.